TOPIC : Unlocking the Solute Carrier Gene-Family for Effective New Therapies (Unlock SLCs)
|Publication date:||21 December 2016|
|Types of action:||IMI2-RIA Research and Innovation action|
|DeadlineModel: Opening date:||two-stage 04 January 2017||Deadline: 2nd stage Deadline:||
28 March 2017 17:00:00
19 October 2017 17:00:00
|Time Zone : (Brussels time)|
Topic DescriptionSpecific Challenge:
The healthy functioning of living cells requires strict control over the import and export of ions, metabolites and nutrients across membranes. Highly regulated transport proteins fulfil this role, and it has been estimated that ~10% of the human genome is linked to membrane transport. The solute carrier (SLC) family is the largest class of such proteins (~400 members), and SLCs play vital roles across practically all cell types in all tissues. The importance of SLCs in disease can be illustrated by human genetic data which suggest that roughly 50% of SLCs are associated with a human disease-related phenotype compared to a rate of only ~20% for the broader human genome. A significant barrier to the study of SLCs is gaining access to relevant reagents and cell systems in which they are expressed
If these reagents become available it will lead to an acceleration in the discovery of effective new medicines for patients suffering from a range of diseases, to the benefit of society at largeScope:
This topic aims to unlock the therapeutic potential within the SLC gene family by overcoming many of the technical barriers that have hindered their study and prevented their exploitation as drug targets by generating research tools and by making them freely available to the scientific community.Expected Impact:
- New open access research tools, techniques, reagents, and knowledge to the biomedical research community that will rapidly accelerate the pace of research in the field of SLCs. These advances are expected to impact both basic research and drug discovery alike.
- The discovery of new drug targets. Since SLCs are expressed in practically all cell types across all tissues, their therapeutic potential spans many disease areas, including, oncology, immunology, neurosciences, metabolism and cardiovascular diseases.
- This project will benefit patients and society through the accelerated discovery of new drugs targeting SLCs which will provide effective therapies for broad range of diseases..
Topic conditions and documents
Please read carefully all provisions below before the preparation of your application.
You can access the description of the different topics in the Call 10 topics text.
The budget breakdown for this Call is given at the end of the Call topics text, in the Conditions for this Call for proposals section, as well as the following information :
- List of countries and applicable rules for funding
- Eligibility and admissibility conditions
- Evaluation criteria and procedure, scoring and treshold: described in the IMI2 Manual for evaluation, submission and grant award.
- Indicative timetable for evaluation and grant agreement
- Provisions, proposal templates and evaluation forms for the type of actions under the Call topics:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Proposal templates are available after entering the submission tool
Standard evaluation form
IMI2 Model Grant Agreement
Template for essential clinical trials information
No submission system is open for this topic.
Contact the IMI Programme Office : E-mail: Infodesk@imi.europa.eu | Tel : +32 2 221 81 81
Contact you SRG member for assistance: IMI States Representative Group (SRG)
IMI Partner Search Tool helps you find a partner organisation for your proposal.
IT Helpdesk- contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
National Contact Points (NCP) - contact your NCP for further assistance.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
Ethics – for compliance with ethical issues, check the information available on the Participant Portal, on the Science and Society Portal and in the The European Charter for Researchers and the Code of Conduct for their recruitment
IP – European IPR Helpdesk assists you on intellectual property issues
CEN and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at email@example.com.